CureVac (NASDAQ:CVAC – Get Rating) gapped up before the market opened on Thursday . The stock had previously closed at $9.48, but opened at $10.35. CureVac shares last traded at $9.74, with a volume of 41,520 shares traded.
Analyst Ratings Changes
A number of equities research analysts recently weighed in on CVAC shares. JMP Securities decreased their price objective on CureVac from $37.00 to $34.00 and set a “market outperform” rating for the company in a research note on Thursday, November 17th. UBS Group upgraded CureVac from a “neutral” rating to a “buy” rating and set a $18.00 price objective for the company in a research note on Thursday. They noted that the move was a valuation call. Finally, Jefferies Financial Group upgraded CureVac from a “hold” rating to a “buy” rating and set a $21.00 price objective for the company in a research note on Friday, January 6th.
CureVac Price Performance
The business has a 50 day simple moving average of $7.82 and a 200 day simple moving average of $9.48. The company has a quick ratio of 3.56, a current ratio of 3.61 and a debt-to-equity ratio of 0.06.
Institutional Inflows and Outflows
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza.
- Get a free copy of the StockNews.com research report on CureVac (CVAC)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
Receive News & Ratings for CureVac Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CureVac and related companies with MarketBeat.com's FREE daily email newsletter.